Skip to main content
Image coming soon

GEN5100 Mastering Rescued Compound Prioritization

$199.00
Adding to cart… The item has been added

The Executive Diagnostic and Governance Toolkit

Mastering Rescued Compound Prioritization

Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide which previously abandoned compounds to prioritize for clinical retesting and regulatory approval.

$199 one-time
30-day money-back guarantee Verified against latest insights, updated access provided within 24h

Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.

What you walk out with
A scored, ranked picture of your own function, and a defensible answer to what to fix first.
1 You stop guessing where you stand.
You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis.
2 You can defend the decision.
You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language.
3 The work actually moves.
The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total.
4 You use it the day it lands.
No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over.
The Quick Scan is one sitting. You will know your weakest area before the day is out.
Nothing in it is generic project management: the build rejects any file that could belong to another course. Updated after you enrol, so it reflects where the work stands now. The 144-chapter course is included behind it, for the parts you want to go deeper on.
You hold the fate of resurrected molecules in your hands—but the data is messy, the stakes are high, and the criteria are unclear.

The situation this is built for

Every abandoned compound carries a legacy of uncertainty. Old trial results, incomplete biomarker data, shifting regulatory expectations—these are the fragments you must assemble into a credible case for retesting. Without a rigorous, defensible framework, decisions default to intuition or hierarchy. You need more than hindsight. You need a method that stands up in front of the development committee, the safety board, and the regulatory liaison. This course gives you that method.

Who this is for

Senior pharmacologist leading the reevaluation of previously discontinued compounds, accountable for go/no-go decisions and alignment with clinical, regulatory, and commercial strategy.

Who this is not for

Researchers focused solely on novel discovery, clinicians without compound prioritization responsibilities, or vendors selling decision-support software.

What you walk away with

  • A repeatable framework for evaluating legacy compounds
  • Clear criteria to differentiate viable from non-viable candidates
  • Improved confidence in presenting recommendations to governance bodies
  • Stronger alignment between pharmacological evidence and development strategy
  • Reduced ambiguity in cross-functional decision meetings

How this maps to your situation

  • Initial compound screening and triage
  • Deep pharmacological and safety reanalysis
  • Cross-functional decision making
  • Long-term pipeline sustainability

Before vs. after

Before
Operating without a consistent method, relying on fragmented data and subjective judgment to decide which failed compounds to revive.
After
Applying a rigorous, defensible framework that transforms ambiguous legacies into prioritized, actionable development opportunities.

What's included with your purchase

  • 12 modules with 12 chapters each (144 chapters)
  • Downloadable templates and worked examples for every module
  • Hand-built implementation playbook delivered alongside course access
  • 30-day money-back guarantee

Delivery and format

  • Course and learning environment access provisioned within 24 hours of purchase
  • Hand-built implementation playbook delivered alongside course access

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.

Time investment: Approximately 3 hours per module, designed to be completed alongside regular responsibilities over 12 weeks.

If nothing changes
Continuing without a structured approach risks misallocating resources on compounds with unresolved flaws, missing viable candidates due to outdated interpretations, and undermining credibility in governance discussions.

How this compares to the alternatives

Unlike generic portfolio management courses or vendor tools, this course focuses exclusively on the pharmacological, regulatory, and strategic nuances of reevaluating discontinued compounds—giving you a tailored, field-specific methodology rather than a one-size-fits-all framework.

Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)

Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.

Module 1. Foundations of Compound Reevaluation
Establish the scientific and strategic principles guiding the reevaluation of discontinued candidates.
12 chapters in this module
  1. Understanding the historical context of compound discontinuation
  2. Mapping the original development pathway and endpoints
  3. Identifying key decision points in prior governance
  4. Classifying reasons for termination by evidence strength
  5. Differentiating safety-driven from efficacy-driven failures
  6. Assessing relevance of original indications today
  7. Evaluating changes in disease understanding since discontinuation
  8. Recognizing shifts in regulatory expectations over time
  9. Defining the scope of reevaluation activities
  10. Aligning reevaluation goals with portfolio strategy
  11. Documenting assumptions in historical trial design
  12. Structuring the initial compound assessment memo
Module 2. Reconstructing Pharmacological Profiles
Rebuild complete pharmacokinetic and pharmacodynamic models using fragmented legacy data.
12 chapters in this module
  1. Gathering all available PK datasets from prior studies
  2. Reconciling inconsistent sampling schedules across trials
  3. Estimating clearance and volume of distribution from sparse data
  4. Reconstructing exposure-response relationships for efficacy
  5. Mapping metabolite profiles and their pharmacological activity
  6. Assessing target engagement evidence from indirect markers
  7. Evaluating duration of effect beyond observed data
  8. Identifying nonlinearities in dose-exposure relationships
  9. Accounting for population variability in original cohorts
  10. Reassessing therapeutic index with modern safety thresholds
  11. Integrating preclinical findings with human observations
  12. Producing a consolidated pharmacological summary document
Module 3. Evaluating Target Validity Revisited
Reassess the biological rationale for the target using current knowledge.
12 chapters in this module
  1. Tracing the original target hypothesis to current understanding
  2. Reviewing genetic evidence supporting target involvement
  3. Analyzing post-discontinuation literature on target biology
  4. Assessing target expression patterns in relevant patient populations
  5. Evaluating functional consequences of target modulation
  6. Comparing target selectivity against known off-target effects
  7. Examining co-morbidities linked to target pathways
  8. Assessing tissue distribution and accessibility of the target
  9. Validating target engagement using modern biomarkers
  10. Reconsidering target relevance in light of new disease subtypes
  11. Identifying competing agents against the same target
  12. Documenting target confidence level for governance review
Module 4. Interpreting Incomplete Efficacy Data
Extract meaningful signals from underpowered or terminated efficacy trials.
12 chapters in this module
  1. Identifying primary and secondary endpoints in original design
  2. Assessing statistical power of completed trial arms
  3. Reanalyzing efficacy signals using Bayesian approaches
  4. Differentiating noise from biological trends in small datasets
  5. Evaluating consistency of response across subgroups
  6. Assessing duration of effect in early termination scenarios
  7. Reinterpreting dose-response relationships with updated models
  8. Evaluating clinical meaningfulness of observed changes
  9. Mapping patient-reported outcomes to modern standards
  10. Assessing functional improvement metrics in context
  11. Comparing results to contemporary standard of care
  12. Producing a critical efficacy assessment memorandum
Module 5. Reassessing Safety and Tolerability
Evaluate historical safety findings against current risk tolerance.
12 chapters in this module
  1. Compiling all adverse event reports from prior studies
  2. Classifying safety signals by severity and frequency
  3. Assessing organ-specific toxicity with modern biomarkers
  4. Reevaluating cardiovascular risk using current standards
  5. Analyzing liver enzyme elevations in context of new guidelines
  6. Evaluating renal safety with updated monitoring practices
  7. Assessing QT prolongation risk with current modeling tools
  8. Reviewing immunogenicity data for biologics and peptides
  9. Evaluating long-term safety in short-duration trials
  10. Comparing safety profile to同类 compounds in development
  11. Determining acceptable risk thresholds for new indication
  12. Documenting safety reassessment for development committee
Module 6. Bridging to Modern Trial Design
Adapt legacy data to inform current study protocols and endpoints.
12 chapters in this module
  1. Translating historical endpoints to current clinical measures
  2. Defining appropriate patient populations for retesting
  3. Selecting biomarkers aligned with current understanding
  4. Designing dose selection strategies based on old PK
  5. Choosing control arms in the context of current standards
  6. Incorporating adaptive design elements where feasible
  7. Aligning with regulatory expectations for confirmatory studies
  8. Planning for early futility assessments
  9. Incorporating patient-centric endpoints in new protocols
  10. Ensuring statistical robustness in follow-on trials
  11. Mapping required preclinical work before reinitiation
  12. Preparing a trial design rationale document
Module 7. Regulatory Pathway Reassessment
Determine viable regulatory strategies for previously discontinued agents.
12 chapters in this module
  1. Identifying potential for accelerated approval pathways
  2. Assessing orphan drug designation eligibility today
  3. Evaluating fast track or breakthrough therapy potential
  4. Reviewing prior regulatory correspondence for insights
  5. Determining whether prior issues were resolvable
  6. Assessing labeling implications of new indications
  7. Planning interactions with regulatory agencies
  8. Preparing briefing packages for pre-submission meetings
  9. Addressing previous deficiencies in regulatory response
  10. Aligning development plan with regional requirements
  11. Evaluating pediatric investigation requirements
  12. Documenting regulatory strategy for governance
Module 8. Commercial and Strategic Fit
Evaluate the market and portfolio relevance of revived compounds.
12 chapters in this module
  1. Assessing unmet medical needs in target indication
  2. Mapping competitive landscape for the mechanism
  3. Evaluating current standard of care and treatment gaps
  4. Projecting market size and growth trends
  5. Assessing payer receptivity to new entrants
  6. Evaluating pricing potential in current environment
  7. Aligning with company therapeutic area strategy
  8. Assessing portfolio fit and resource allocation
  9. Evaluating lifecycle management opportunities
  10. Considering combination therapy potential
  11. Weighing development costs against projected returns
  12. Producing a strategic fit assessment report
Module 9. Cross-Functional Alignment
Secure consensus across development, safety, and commercial teams.
12 chapters in this module
  1. Identifying key stakeholders in reevaluation process
  2. Facilitating alignment on compound potential
  3. Presenting pharmacological evidence to non-specialists
  4. Addressing clinical development concerns
  5. Incorporating safety team risk assessments
  6. Engaging regulatory affairs early in the process
  7. Involving commercial strategy in prioritization
  8. Managing differing interpretations of legacy data
  9. Documenting areas of agreement and disagreement
  10. Building a shared decision framework
  11. Scheduling joint review meetings with clear agendas
  12. Producing a consolidated cross-functional assessment
Module 10. Decision Frameworks and Governance
Structure formal processes for compound prioritization and escalation.
12 chapters in this module
  1. Defining go/no-go criteria for retesting
  2. Establishing scoring system for compound viability
  3. Creating weighted evaluation matrices
  4. Setting thresholds for advancement decisions
  5. Designing escalation pathways for borderline cases
  6. Preparing materials for development oversight committee
  7. Structuring decision memos with clear recommendations
  8. Incorporating risk tolerance into governance
  9. Documenting rationale for compound deprioritization
  10. Ensuring traceability of key judgments
  11. Reviewing decisions post-hoc for process improvement
  12. Maintaining a compound prioritization register
Module 11. Implementation and Monitoring
Execute reevaluation decisions and track performance.
12 chapters in this module
  1. Translating decisions into action plans
  2. Assigning ownership for next steps
  3. Scheduling follow-up data collection activities
  4. Tracking progress against reevaluation timeline
  5. Updating compound status in portfolio database
  6. Communicating decisions to broader teams
  7. Planning for preclinical retesting if needed
  8. Initiating new clinical protocol development
  9. Monitoring external developments affecting compound
  10. Scheduling periodic reassessment of paused candidates
  11. Updating risk-benefit profile with new information
  12. Maintaining audit trail of all evaluations
Module 12. Sustaining the Revival Pipeline
Build a long-term, scalable process for ongoing compound reevaluation.
12 chapters in this module
  1. Designing a continuous compound screening process
  2. Establishing intake criteria for new candidates
  3. Creating standardized assessment templates
  4. Training team members on evaluation methodology
  5. Integrating reevaluation into portfolio reviews
  6. Building knowledge repository for past decisions
  7. Implementing feedback loops from clinical retesting
  8. Updating criteria based on new evidence
  9. Measuring success of reevaluation function
  10. Optimizing resource allocation over time
  11. Aligning with external collaboration opportunities
  12. Ensuring regulatory readiness for future submissions

Frequently asked

Who is this course designed for?
Senior pharmacologists responsible for evaluating previously discontinued drug candidates and making go/no-go decisions for retesting.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Does this course cover new technologies or software tools?
No. The course focuses on the scientific and strategic decision-making process, not on specific technologies or vendors.
Will I learn how to present my assessments to leadership?
Yes. Each module includes guidance on producing clear, defensible documentation for governance and cross-functional review.
Is there a practical component?
Yes. The course includes downloadable templates and a hand-built implementation playbook to apply the framework directly to your work.
What formats do the templates come in?
The implementation playbook downloads as PDF and editable XLSX. The course reads in your learning environment and exports to PDF for offline use. The files are yours to keep.
Can I share this with my team?
The licence is per person. Team pricing opens from three seats: reply to the order confirmation with TEAM and we will set it up.
How quickly can I start?
The diagnostic is one sitting and the templates work straight out of the kit. Account access takes up to 24 hours rather than being instant, because every order is checked and updated against the latest sources before it is delivered.
$199 one-time. Approximately 3 hours per module, designed to be completed alongside regular responsibilities over 12 weeks..

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.

30-day money-back guarantee·Know your weakest area today·210 scored questions·Course included· Account access within 24 hours
30-day money-back guarantee, no questions asked.
Thousands of organisations have bought from The Art of Service since 2000.
!